The data are compelling and consistent–OMIDRIA makes cataract surgery better for you and your patientsPublished and presented clinical studies report that in post-launch (i.e., not included in current labeling), prospective and retrospective, double-masked and open-label, cohort and case-controlled, single- and multi-center analyses, the use of OMIDRIA, compared to the surgeons’ standard of care, statistically significantly:
- Prevents Intraoperative Floppy Iris Syndrome (IFIS)14
- Reduces complication rates (epinephrine comparator)2
- Decreases use of pupil-expanding devices (epinephrine comparator)2,7,15-18
- Reduces surgical times (epinephrine comparator)2,7,15,18
- Prevents miosis during femtosecond laser-assisted surgery (epinephrine comparator)17,19
- Improves uncorrected visual acuity on day after surgery (epinephrine comparator)2
- Delivers NSAID to the anterior chamber and related structures better than routine preoperative topical drug administration, resulting in effectively complete postoperative inhibition of COX-1 and COX-211,20
Reduces complication rates2
Patients who received OMIDRIA had fewer intraoperative and postoperative complications, including capsular tears, lens decentration, retained lens fragments, macular puckering, and retinal detachment.
Retrospective case review. Co-author E. Donnenfeld is a consultant for Omeros.
Reduces surgical time and pupil-expanding device use18
In the OMIDRIA group, use of pupil-expanding devices (PED) was reduced by 67% and surgical time was reduced by 7.3%.
Retrospective case review, single surgeon, two centers. Omeros Corporation provided support for this study. C. Matossian is a consultant for Omeros.
Reduces use of pupil-expanding devices in high-risk patients and in femtosecond laser surgery15,17
With OMIDRIA, zero patients at risk for intraoperative miosis* required pupil-expanding devices.
- Additionally, mean surgical time with OMIDRIA was significantly shorter compared to epinephrine (10.1 vs 14.3 minutes; p=0.0068) in high-risk patients
Retrospective case review analysis of patients at risk for requiring a pupil-expanding device. Dr Visco is a consultant for Omeros Corporation, which provided financial support for this study.
|*||Patients with presurgical examination of pupil dilation ≤5.0 mm after being administered topical tropicamide 1% and phenylephrine 2.5% or history of IFIS during surgery in the fellow eye.15|
With OMIDRIA, there was an 83% reduction in pupil-expanding device usage in femtosecond laser surgeries.
- Additionally, mean surgical time with OMIDRIA was significantly shorter compared to epinephrine (8.10 vs 9.39 minutes; p=0.007) in femtosecond laser-assisted cataract surgeries
Retrospective case review analysis of patients undergoing femtosecond laser-assisted cataract surgery. Dr Walter is a consultant for Omeros Corporation.
The OMIDRIA group had an 87% overall reduction in observed IFIS symptoms, 79% reduction in iris prolapse, and 90% reduction in severe billowing.
Investigator-initiated, double-masked study in 50 male patients (50 eyes). Dr Silverstein is a consultant for Omeros Corporation.